Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.3 (market cap $40.01B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.79 (market cap $25.27B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is the larger of the two by market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| HLN | RPRX | |
|---|---|---|
Market Cap | $40.01B | $25.27B |
Volume | 19,985,935 | 3,671,183 |
Sector | Health | Health |
52-Week High | $11.27 | $63.96 |
52-Week Low | $8.70 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $49.79B | $32.50B |
Dividend Yield | 2.14% | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
